Profil
Ingmar Bruns worked as the Chief Medical Officer at Trillium Therapeutics ULC from 2020 to 2021.
Prior to that, he held the position of Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns earned a doctorate degree from Universität zu Lübeck.
Anciens postes connus de Ingmar Bruns
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Directeur Technique/Scientifique/R&D | 17/11/2021 |
| PIERIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Ingmar Bruns
| Universität zu Lübeck | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
